A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy

被引：1

作者：

Laouenan, C. ^{[1
,2
]}

Guedj, J. ^{[1
]}

Peytavin, G. ^{[1
,3
]}

Nguyen, T. H. Tram ^{[1
]}

Lapalus, M. ^{[4
]}

Khelifa-Mouri, F. ^{[5
]}

Boyer, N. ^{[5
]}

Zoulim, F. ^{[6
,7
]}

Serfaty, L. ^{[8
]}

Bronowicki, J-P ^{[9
,10
]}

Martinot-Peignoux, M. ^{[4
]}

Lada, O. ^{[4
]}

Asselah, T. ^{[4
,5
]}

Dorival, C. ^{[11
]}

Hezode, C. ^{[12
,13
]}

Carrat, F. ^{[11
,14
]}

Nicot, F. ^{[15
]}

Marcellin, P. ^{[4
,5
]}

Mentre, F. ^{[1
,2
]}

机构：

[1] Univ Paris Diderot, IINSERM, IAME, UMR 1137, Paris, France

[2] Hop Bichat Claude Bernard, AP HP, Dept Biostat, Paris, France

[3] Hop Bichat Claude Bernard, AP HP, Dept Pharmaco Toxicol, Paris, France

[4] Univ Paris Diderot, INSERM, CRI Paris Montmartre, UMR 1149, Clichy, France

[5] Hop Beaujon, AP HP, Hepatol Physiopathol & Treatment Viral Hepatitis, Clichy, France

[6] Univ Lyon, INSERM, UMR 1052, Lyon, France

[7] Hosp Civils Lyon, Dept Hepatol, Lyon, France

[8] Hop St Antoine, AP HP, Dept Hepatol, Paris, France

[9] Univ Lorraine, INSERM, UMR 954, Vandoeuvre Ies Nancy, France

[10] Ctr Hosp Univ Nancy, Dept Hepatol, Vandoeuvre Ies Nancy, France

[11] Univ Paris 06, INSERM, UMR 1136, Paris, France

[12] Univ Paris Est, INSERM, UMR 955, Creteil, France

[13] Hop Henri Mondor, AP HP, Dept Hepatol, Creteil, France

[14] Hop St Antoine, AP HP, Dept Publ Hlth, Paris, France

[15] CHU Toulouse, IFB Purpan, Virol Lab Toulouse, Toulouse, France

来源：

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2015年 / 4卷 / 01期

关键词：

D O I：

10.1002/psp4.8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hezode et al. recently reported the frequent occurrence of anemia and thrombocytopenia in the ANRS-CO20-CUPIC cohort of hepatitis C virus (HCV) cirrhotic experienced patients treated with pegylated-interferon (Peg-IFN), ribavirin (RBV), and telaprevir or boceprevir. (1,2) Using frequent measurements of serum drug concentrations, hemoglobin, and platelet concentrations obtained in 15 patients of this cohort, we show how an on-treatment model-based approach could be used to individualize dose regimen and avoid the occurrence of RBV-induced anemia and Peg-IFN-induced thrombocytopenia.

引用

页码：37 / 40

页数：4

共 50 条

[1] Efficacy of Rikkunshito on Anorexia in Chronic Hepatitis C Patients During PEG-IFN/RBV Therapy
Arai, Makoto
Matsumura, Tomoaki
Maruoka, Daisuke
Nakagawa, Tomoo
Katsuno, Tatsuro
Imazeki, Fumio
Yokosuka, Osamu
GASTROENTEROLOGY, 2013, 144 (05) : S568 - S568
[2] Predictive Factors for Silibinin Monotherapy in Patients With Chronic Hepatitis C and Nonresponse to PEG-IFN/RBV Therapy
Rutter, Karoline
Stattermayer, Albert
Reiberger, Thomas
Aberle, Judith H.
Zinober, Kerstin
Scherzer, Thomas-Matthias
Beinhardt, Sandra
Holzmann, Heidemarie
Steindl-Munda, Petra
Hofer, Harald
Ferenci, Peter
GASTROENTEROLOGY, 2010, 138 (05) : S214 - S215
[3] PREDICTIVE FACTORS FOR SILIBININ MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND NONRESPONSE TO PEG-IFN/RBV THERAPY
Rutter, K.
Staettermayer, A.
Reiberger, T.
Aberle, J.
Zinober, K.
Scherzer, T. -M.
Beinhardt, S.
Holzmann, H.
Steindl-Munda, P.
Hofer, H.
Ferenci, P.
JOURNAL OF HEPATOLOGY, 2010, 52 : S124 - S124
[4] Hepatitis C Virus Genotypes Circulating in Patients With Chronic Hepatitis C in Thailand and Their Responses to Combined PEG-IFN and RBV Therapy
Kumthip, Kattareeya
Chusri, Pattranuch
Pantip, Chansom
Thongsawat, Satawat
O'Brien, Amornrat
Nelson, Kenrad E.
Maneekarn, Niwat
JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (08) : 1360 - 1365
[5] Final results of patients treated with Peg-interferon-alfa-2a (Peg-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the Hepatitis C protease inhibitor telaprevir (VX-950), Peg-IFN and RBV
Rodriguez-Torres, Maribel
Lawitz, Eric J.
McHutchison, John G.
HEPATOLOGY, 2007, 46 (04) : 314A - 315A
[6] Diabetes mellitus is a predictor of treatment failure in hepatitis C patients treated with PEG IFN and RBV
Elgoubari, Hesharn M.
Hanouneh, Ibrahim
Zein, Claudia O.
Feldstein, Ariel E.
Zein, Nizar N.
GASTROENTEROLOGY, 2007, 132 (04) : A779 - A779
[7] Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV)
Younossi, Zobair M.
Limongi, Dolores
Stepanova, Maria
Pierobon, Mariaelena
Afendy, Arian
Mehta, Rohini
Baranova, Ancha
Liotta, Lance
Petricoin, Emanuel
JOURNAL OF PROTEOME RESEARCH, 2011, 10 (02) : 774 - 779
[8] Retreatment of patients with Hepatitis C and failure of previous treatment with peg-ifn and RBV (agora study): results at week 12
Solo, Ricard
Diago, Moises
Crespo, Javier
Dalmau, Blai
Morillas, Rosa Maria
Suarez, Dolores
Bonet, Lucia
Montoliu, Silvia
Cervantes, Francesc Xavier
Planas, Ramon
Garcia-Samaniego, Javier
Romero-Gomez, Manuel
Calleja, Jose L.
HEPATOLOGY, 2012, 56 : 665A - 666A
[9] Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients
Gane, Edward J.
Rouzier, Regine
Stedman, Catherine
Wiercinska-Drapalo, Alicja
Horban, Andrzej
Chang, Linda
Zhang, Ying
Sampeur, Pratibha
Najera, Isabel
Smith, Patrick
Shulman, Nancy S.
Tran, Jonathan Q.
JOURNAL OF HEPATOLOGY, 2011, 55 (05) : 972 - 979
[10] Efficacy of PEG-IFN/RBV and benefit from viral eradication against HCC in chronic hepatitis C patients in Japan
Asahina, Yasuhiro
Izumi, Namiki
Hirayama, Itsuko
Sato, Mitsuaki
Tanaka, Tomohiro
Komatsu, Nobutoshi
Umeda, Naoki
Hosokawa, Takanori
Ueda, Ken
Tsuchiya, Kaoru
Nakanishi, Hiroyuki
Itakura, Jun
Kurosaki, Masayuki
Uchihara, Masakatsu
Miyake, Shozo
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : A114 - A114

← 1 2 3 4 5 →